Roche, Zealand Pharma Advance Amylin Analog Petrelintide to Phase 3 Trials
Event summary
- Zealand Pharma and Roche are advancing petrelintide, an amylin analog, into Phase 3 trials for chronic weight management, planned to begin in 2H 2026.
- Phase 2 (ZUPREME-1) data showed double-digit weight loss with placebo-like tolerability.
- The Phase 3 program will evaluate efficacy, safety, and tolerability in adults with obesity or overweight and weight-related comorbidities.
- Zealand Pharma and Roche entered an exclusive collaboration and licensing agreement in 2025.
- A Phase 2 trial combining petrelintide and Roche’s enicepatide (CT-388) is planned for 2Q 2026.
The big picture
The advancement of petrelintide represents a significant step in the ongoing race to develop more effective and tolerable weight management therapies. The obesity market is a multi-billion dollar opportunity, and the collaboration between Zealand Pharma and Roche, a major pharmaceutical player, underscores the growing recognition of amylin analogs as a potential therapeutic avenue. The combination strategy with Roche’s enicepatide suggests a focus on maximizing efficacy and addressing the limitations of monotherapy.
What we're watching
- Clinical Efficacy
- The Phase 3 trial results will be critical in determining whether petrelintide’s efficacy can be replicated in a larger, more diverse patient population, and whether it offers a clinically meaningful advantage over existing therapies.
- Combination Strategy
- The success of the planned Phase 2 trial combining petrelintide and enicepatide will significantly influence Roche’s commercial strategy and the overall value proposition of petrelintide.
- Market Dynamics
- The competitive landscape in the weight management market is rapidly evolving, and petrelintide’s success will depend on its ability to differentiate itself from emerging GLP-1/GIP dual agonists and other novel therapies.
Related topics